142 related articles for article (PubMed ID: 30717758)
1. Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors.
Wang Z; Zuo W; Zeng Q; Qian Y; Li Y; Liu C; Wang J; Zhong S; Bu Y; Hu G
J Biomed Sci; 2019 Feb; 26(1):14. PubMed ID: 30717758
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells.
Zeng Q; Wang Z; Liu C; Gong Z; Yang L; Jiang L; Ma Z; Qian Y; Yang Y; Kang H; Hong S; Bu Y; Hu G
Mol Cell Biochem; 2016 Jul; 418(1-2):137-46. PubMed ID: 27334757
[TBL] [Abstract][Full Text] [Related]
3. Depletion of NFBD1/MDC1 Induces Apoptosis in Nasopharyngeal Carcinoma Cells Through the p53-ROS-Mitochondrial Pathway.
Wang Z; Liao K; Zuo W; Liu X; Qiu Z; Gong Z; Liu C; Zeng Q; Qian Y; Jiang L; Bu Y; Hong S; Hu G
Oncol Res; 2017 Jan; 25(1):123-136. PubMed ID: 28081741
[TBL] [Abstract][Full Text] [Related]
4. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
[TBL] [Abstract][Full Text] [Related]
5. Silencing NFBD1/MDC1 enhances the radiosensitivity of human nasopharyngeal cancer CNE1 cells and results in tumor growth inhibition.
Wang Z; Zeng Q; Chen T; Liao K; Bu Y; Hong S; Hu G
Cell Death Dis; 2015 Aug; 6(8):e1849. PubMed ID: 26247734
[TBL] [Abstract][Full Text] [Related]
6. NFBD1/MDC1 participates in the regulation of proliferation and apoptosis in human laryngeal squamous cell carcinoma.
Liu X; Qiu Z; Wang Z; Zuo W; Gong Z; Liu C; Zeng Q; Qian Y; Jiang L; Li Y; Bu Y; Hu G
Clin Transl Oncol; 2018 Apr; 20(4):534-541. PubMed ID: 28921460
[TBL] [Abstract][Full Text] [Related]
7. NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53.
Wilson KA; Colavito SA; Schulz V; Wakefield PH; Sessa W; Tuck D; Stern DF
Mol Cancer Res; 2011 Jun; 9(6):766-81. PubMed ID: 21551225
[TBL] [Abstract][Full Text] [Related]
8. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition, morphology change, and cell cycle alterations in NFBD1-depleted human esophageal cancer cells.
Yang Z; Bu Y; Wang C; Liu G; Song F
Mol Cell Biochem; 2010 Sep; 342(1-2):1-6. PubMed ID: 20364298
[TBL] [Abstract][Full Text] [Related]
10. O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma.
Chen SH; Huang WT; Kao WC; Hsiao SY; Pan HY; Fang CW; Shiue YL; Chou CL; Li CF
J Biomed Sci; 2021 Jan; 28(1):2. PubMed ID: 33397362
[TBL] [Abstract][Full Text] [Related]
11. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.
Maeda J; Haskins JS; Kato TA
Mutat Res; 2023; 826():111815. PubMed ID: 36812659
[TBL] [Abstract][Full Text] [Related]
12. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
13. NFBD1/MDC1 is a protein of oncogenic potential in human cervical cancer.
Yuan C; Bu Y; Wang C; Yi F; Yang Z; Huang X; Cheng L; Liu G; Wang Y; Song F
Mol Cell Biochem; 2012 Jan; 359(1-2):333-46. PubMed ID: 21853275
[TBL] [Abstract][Full Text] [Related]
14. The Homologous Recombination Repair Pathway is Associated with Resistance to Radiotherapy in Nasopharyngeal Carcinoma.
Wang Z; Zuo W; Zeng Q; Li Y; Lu T; Bu Y; Hu G
Int J Biol Sci; 2020; 16(3):408-419. PubMed ID: 32015678
[TBL] [Abstract][Full Text] [Related]
15. NFBD1/MDC1 stabilizes oncogenic MDM2 to contribute to cell fate determination in response to DNA damage.
Inoue K; Nakanjishi M; Kikuchi H; Yamamoto H; Todo S; Nakagawara A; Ozaki T
Biochem Biophys Res Commun; 2008 Jul; 371(4):829-33. PubMed ID: 18471438
[TBL] [Abstract][Full Text] [Related]
16. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
Koppensteiner R; Samartzis EP; Noske A; von Teichman A; Dedes I; Gwerder M; Imesch P; Ikenberg K; Moch H; Fink D; Stucki M; Dedes KJ
PLoS One; 2014; 9(6):e100041. PubMed ID: 24927325
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
18. NFBD1/MDC1 participates in the regulation of G2/M transition in mammalian cells.
Bu Y; Suenaga Y; Okoshi R; Sang M; Kubo N; Song F; Nakagawara A; Ozaki T
Biochem Biophys Res Commun; 2010 Jun; 397(2):157-62. PubMed ID: 20529673
[TBL] [Abstract][Full Text] [Related]
19. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
Jian W; Xu HG; Chen J; Xu ZX; Levitt JM; Stanley JA; Yang ES; Lerner SP; Sonpavde G
Anticancer Drugs; 2014 Sep; 25(8):878-86. PubMed ID: 24714082
[TBL] [Abstract][Full Text] [Related]
20. MDC1 interacts with Rad51 and facilitates homologous recombination.
Zhang J; Ma Z; Treszezamsky A; Powell SN
Nat Struct Mol Biol; 2005 Oct; 12(10):902-9. PubMed ID: 16186822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
